GRFS News and Press, Grifols S.A. From 08/13/20

Results from a large-scale study involving more than 35K severely ill COVID-19 patients demonstrated that the early administration of convalescent plasma, derived from patients who recovered from the infection and who generated antibodies against SARS-CoV-2, lowered the mortality rate. ...

SAN CLEMENTE, Calif., Aug. 10, 2020 /PRNewswire/ --  ICU Medical Inc. (NASDAQ: ICUI) today announced that it has entered into a long-term agreement with Grifols to distribute a full line of non-PVC/non-DEHP IV containers for 0.9% Sodium Chloride Injection, USP to customers in ...

A clinical research study led by the Mayo Clinic has achieved promising results in COVID-19 patients by administering them so-called "convalescent plasma" -- plasma enriched with high levels of antibodies from people who have recovered from the novel coronavirus. According to a Wall Street ...

Grifols ( GRFS +1.9% ) announces the delivery of the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin to U.S. healthcare agencies for use in COVID-19 clinical trials, expected to launch in the coming weeks. More news on: Grifols, S.A., Kamada Ltd., XBiotech Inc., ...

Grifols (NASDAQ: GRFS ) has acquired 10% of Bloodbuy, a cloud-based marketplace that facilitates buying and selling of blood components in the U.S. More news on: Grifols, S.A., Healthcare stocks news, Read more ...

Disclaimer: This report is the work of an investment adviser affiliated with the author. The report is the result of the adviser executing its investment strategy. The adviser holds a position in the security, however there is no assurance that the adviser will continue to hold the investm...

Grifols (NASDAQ: GRFS ) has executed purchase arrangements with the South Korean-based GC Pharma whereby Grifols will acquire the Montreal-based plasma fractionation facility and two purification facilities, along with 11 U.S.-based plasma collection centers for a total amount of $460M...

SOUTH SAN FRANCISCO, Calif. , July 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Grifols S.A., its collaborative partner in Europe , has launched TAVLESSE ® in Germany and the United Kingdom . It was approved by the European Co...

Since the COVID-19 pandemic swept the world, healthcare stocks have been hotly traded in the face of turbulent and unpredictable market conditions. Whether investors are interested in speculating on price movements spurred by COVID-19 drug and vaccine development or simply chasing reliable ear...

People who had COVID-19 and are now fully recovered may be eligible to donate plasma to help patients currently infected with COVID-19. Their plasma likely contains antibodies that bind and inhibit SARS-CoV-2, the novel coronavirus that causes COVID-19. The American Red Cross requires donors...